Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is supported by a resilient growth outlook as it maintains expectations for 2026 high-single digit top-line growth even after a downward revision to Baqsimi, indicating underlying demand strength across the portfolio. Baqsimi remains a meaningful contributor with peak sales expectations of $250MM-$275MM, and margins are expected to improve in 2H26 as the company discontinues a small amount of international sales, which should enhance profitability. The recent launch of ipratropium bromide HFA has not faced additional competition and could become a $30MM-$40MM sales opportunity, reinforcing the company’s ability to convert product launches into durable revenue growth.

Bears say

Amphastar Pharma is facing a fragile growth profile as core products are being pressured by competition and pricing erosion, with injectable glucagon falling 42% in 2Q26 to $11.9M after Viatris entered generic glucagon and generic epinephrine also softened. Baqsimi, despite 17% prescription growth in 1Q26 and 2Q26, saw sales decline to $32.4M and $45.5M because higher rebates, 340B discounts, and an unfavorable channel mix drove lower net selling prices and margin erosion. The company also lacks near-term catalysts, as next ANDA approvals and potential new products are not expected until 2027, while higher R&D spending and reduced 2027E EBITDA of $204M support a cautious outlook.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.